Mark Breidenbach
Stock Analyst at Oppenheimer
(1.68)
# 3,302
Out of 4,960 analysts
56
Total ratings
32.2%
Success rate
0.39%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Mark Breidenbach
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NRIX Nurix Therapeutics | Maintains: Outperform | $27 → $30 | $10.14 | +195.86% | 4 | Sep 4, 2024 | |
| ALLO Allogene Therapeutics | Maintains: Outperform | $14 → $13 | $1.19 | +992.44% | 5 | May 21, 2024 | |
| EPIX ESSA Pharma | Reiterates: Outperform | $17 | $1.93 | +780.83% | 5 | Dec 13, 2023 | |
| ARVN Arvinas | Reiterates: Outperform | $95 | $7.32 | +1,197.81% | 6 | Aug 9, 2023 | |
| IMRX Immuneering | Reiterates: Outperform | $25 | $4.89 | +411.25% | 3 | Aug 8, 2023 | |
| CUE Cue Biopharma | Assumes: Outperform | $10 | $0.83 | +1,110.65% | 6 | Jun 26, 2023 | |
| MCRB Seres Therapeutics | Assumes: Outperform | $240 | $19.44 | +1,134.57% | 4 | Jun 26, 2023 | |
| BLRX BioLineRx | Reiterates: Outperform | $160 | $3.74 | +4,178.07% | 1 | May 25, 2023 | |
| CGEN Compugen | Maintains: Outperform | $8 → $7 | $1.45 | +382.76% | 7 | May 16, 2023 | |
| CRBU Caribou Biosciences | Maintains: Outperform | $36 → $32 | $1.85 | +1,629.73% | 2 | Mar 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $25 → $15 | $2.69 | +457.62% | 7 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $90 → $120 | $1.46 | +8,119.18% | 4 | Oct 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $11,250 → $9,750 | $1.65 | +590,809.09% | 2 | May 12, 2020 |
Nurix Therapeutics
Sep 4, 2024
Maintains: Outperform
Price Target: $27 → $30
Current: $10.14
Upside: +195.86%
Allogene Therapeutics
May 21, 2024
Maintains: Outperform
Price Target: $14 → $13
Current: $1.19
Upside: +992.44%
ESSA Pharma
Dec 13, 2023
Reiterates: Outperform
Price Target: $17
Current: $1.93
Upside: +780.83%
Arvinas
Aug 9, 2023
Reiterates: Outperform
Price Target: $95
Current: $7.32
Upside: +1,197.81%
Immuneering
Aug 8, 2023
Reiterates: Outperform
Price Target: $25
Current: $4.89
Upside: +411.25%
Cue Biopharma
Jun 26, 2023
Assumes: Outperform
Price Target: $10
Current: $0.83
Upside: +1,110.65%
Seres Therapeutics
Jun 26, 2023
Assumes: Outperform
Price Target: $240
Current: $19.44
Upside: +1,134.57%
BioLineRx
May 25, 2023
Reiterates: Outperform
Price Target: $160
Current: $3.74
Upside: +4,178.07%
Compugen
May 16, 2023
Maintains: Outperform
Price Target: $8 → $7
Current: $1.45
Upside: +382.76%
Caribou Biosciences
Mar 10, 2023
Maintains: Outperform
Price Target: $36 → $32
Current: $1.85
Upside: +1,629.73%
Mar 1, 2023
Maintains: Outperform
Price Target: $25 → $15
Current: $2.69
Upside: +457.62%
Oct 18, 2022
Maintains: Outperform
Price Target: $90 → $120
Current: $1.46
Upside: +8,119.18%
May 12, 2020
Maintains: Outperform
Price Target: $11,250 → $9,750
Current: $1.65
Upside: +590,809.09%